JP2009517016A - 組換え熱帯熱マラリア原虫（Ｐｌａｓｍｏｄｉｕｍｆａｌｃｉｐａｒｕｍ）メロゾイト表面タンパク質４および５およびこれらの使用 - Google Patents

組換え熱帯熱マラリア原虫（Ｐｌａｓｍｏｄｉｕｍｆａｌｃｉｐａｒｕｍ）メロゾイト表面タンパク質４および５およびこれらの使用 Download PDF

Info

Publication number
JP2009517016A
JP2009517016A JP2008541848A JP2008541848A JP2009517016A JP 2009517016 A JP2009517016 A JP 2009517016A JP 2008541848 A JP2008541848 A JP 2008541848A JP 2008541848 A JP2008541848 A JP 2008541848A JP 2009517016 A JP2009517016 A JP 2009517016A
Authority
JP
Japan
Prior art keywords
msp4
recombinant
polypeptide
msp5
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008541848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517016A5 (enExample
Inventor
ロンガクール、シャーリー
ポルソン、ハンナ
ペルロー、ロナルド
ナト、ファリダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of JP2009517016A publication Critical patent/JP2009517016A/ja
Publication of JP2009517016A5 publication Critical patent/JP2009517016A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008541848A 2005-11-23 2006-11-23 組換え熱帯熱マラリア原虫（Ｐｌａｓｍｏｄｉｕｍｆａｌｃｉｐａｒｕｍ）メロゾイト表面タンパク質４および５およびこれらの使用 Withdrawn JP2009517016A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73997305P 2005-11-23 2005-11-23
PCT/IB2006/003967 WO2007060550A2 (en) 2005-11-23 2006-11-23 Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012158992A Division JP2012254082A (ja) 2005-11-23 2012-07-17 組換え熱帯熱マラリア原虫（Ｐｌａｓｍｏｄｉｕｍｆａｌｃｉｐａｒｕｍ）メロゾイト表面タンパク質４および５およびこれらの使用

Publications (2)

Publication Number Publication Date
JP2009517016A true JP2009517016A (ja) 2009-04-30
JP2009517016A5 JP2009517016A5 (enExample) 2010-02-18

Family

ID=38067607

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008541848A Withdrawn JP2009517016A (ja) 2005-11-23 2006-11-23 組換え熱帯熱マラリア原虫（Ｐｌａｓｍｏｄｉｕｍｆａｌｃｉｐａｒｕｍ）メロゾイト表面タンパク質４および５およびこれらの使用
JP2012158992A Withdrawn JP2012254082A (ja) 2005-11-23 2012-07-17 組換え熱帯熱マラリア原虫（Ｐｌａｓｍｏｄｉｕｍｆａｌｃｉｐａｒｕｍ）メロゾイト表面タンパク質４および５およびこれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012158992A Withdrawn JP2012254082A (ja) 2005-11-23 2012-07-17 組換え熱帯熱マラリア原虫（Ｐｌａｓｍｏｄｉｕｍｆａｌｃｉｐａｒｕｍ）メロゾイト表面タンパク質４および５およびこれらの使用

Country Status (6)

Country Link
US (4) US8026354B2 (enExample)
EP (2) EP1954305B1 (enExample)
JP (2) JP2009517016A (enExample)
CN (1) CN101415436A (enExample)
CA (1) CA2630283A1 (enExample)
WO (1) WO2007060550A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
US8026354B2 (en) * 2005-11-23 2011-09-27 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
CN101671654B (zh) * 2009-10-13 2012-11-07 黑龙江八一农垦大学 抗边缘无浆体msp5蛋白的单克隆抗体及其应用
WO2011056216A1 (en) * 2009-11-05 2011-05-12 The United States Of America As Represented By The Secretary Of The Navy Plasmodium falciparum sporozoite and liver stage antigens
CU20100083A7 (es) * 2010-05-05 2012-06-21 Inst Finlay Tolerogenos adyuvados como vacuna de malaria
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
CN102533678A (zh) * 2012-01-10 2012-07-04 特菲(天津)生物医药科技有限公司 一种间日疟红内期疫苗及其制备方法
WO2015055772A1 (en) 2013-10-16 2015-04-23 Shirley Longacre Combination of plasmodium merozoite surface proteins msp4 and 1 and uses thereof
WO2015187652A1 (en) * 2014-06-02 2015-12-10 The Johns Hopkins University Malarial antigens derived from subtilisin-like protease 2 and vaccines and methods of use
US10622025B2 (en) 2018-06-05 2020-04-14 Seagate Technology Llc Carrierless storage chassis
US10354699B1 (en) 2018-06-05 2019-07-16 Seagate Technology Llc Carrierless storage chassis drive locking units
US11304328B2 (en) 2020-01-16 2022-04-12 Seagate Technology Llc Data storage retainer systems, methods, and devices

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527435A (ja) * 2000-03-23 2003-09-16 アクゾ・ノベル・エヌ・ベー 免疫療法におけるｍｉａの使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE69034168T3 (de) 1989-03-21 2013-04-11 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
DE69939327D1 (de) 1998-11-02 2008-09-25 Curis Inc Funktionelle antagonisten von hedgehog-aktivität
AU1818200A (en) * 1998-11-05 2000-05-22 Daniel Carucci Chromosome 2 sequence of the human malaria parasite (plasmodium falciparum) and proteins of said chromosome useful in anti-malarial vaccines and diagnostic reagents
EP1529536A1 (en) * 2003-11-05 2005-05-11 Institut Pasteur Immunogenic composition having improved immunostimulation capacity
US20080260763A1 (en) * 2004-07-01 2008-10-23 The Regents Of The University Of California High Throughput Proteomics
US8026354B2 (en) * 2005-11-23 2011-09-27 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527435A (ja) * 2000-03-23 2003-09-16 アクゾ・ノベル・エヌ・ベー 免疫療法におけるｍｉａの使用

Also Published As

Publication number Publication date
US20120115156A1 (en) 2012-05-10
CA2630283A1 (en) 2007-05-31
EP2329844A1 (en) 2011-06-08
US20130129766A1 (en) 2013-05-23
JP2012254082A (ja) 2012-12-27
WO2007060550A2 (en) 2007-05-31
EP1954305B1 (en) 2012-09-19
US8026354B2 (en) 2011-09-27
EP1954305A2 (en) 2008-08-13
US20100092520A1 (en) 2010-04-15
CN101415436A (zh) 2009-04-22
WO2007060550A3 (en) 2008-01-03
US8350019B2 (en) 2013-01-08
US20080286805A1 (en) 2008-11-20
US8378087B2 (en) 2013-02-19

Similar Documents

Publication Publication Date Title
US8378087B2 (en) Recombinant Plasmodium falciparum merozoite surface proteins 4 and 5 and their use
Baruch et al. Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes
Albano et al. A homologue of Sar1p localises to a novel trafficking pathway in malaria-infected erythrocytes
JP2584733B2 (ja) 原虫類抗原用ｄｎａのクロ−ニング
US5231168A (en) Malaria antigen
Singh et al. Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion
Kaneko et al. Disruption of the C-terminal region of EBA-175 in the Dd2/Nm clone of Plasmodium falciparum does not affect erythrocyte invasion
EP0957937A1 (en) VACCINES, ANTIBODIES, PROTEINS, GLYCOPROTEINS, DNAS AND RNAS FOR PROPHYLAXIS AND TREATMENT OF $i(CRYPTOSPORIDIUM PARVUM) INFECTIONS
Ramasamy et al. Antibodies to a merozoite surface protein promote multiple invasion of red blood cells by malaria parasites
Black et al. MSP8 is a non-essential merozoite surface protein in Plasmodium falciparum
EP1526178B1 (en) MSP-3-like family of genes
CA2480786A1 (en) Recombinant p. falciparum merozoite protein-142 vaccine
EP1590368B1 (en) Compounds useful in the diagnosis and treatment of pregnancy-associated malaria
US6403103B1 (en) Trypanosoma cruzi antigen, gene encoding therefore, and methods of detecting and treating chagas disease
US5646247A (en) Merozoite antigens localized at the apical end of the parasite
US20090324628A1 (en) Compounds useful in the diagnosis and treatment of malaria
WO1990011772A1 (en) Merozoite antigens localized at the apical end of the parasite
HK1075066B (en) Msp-3-like family of genes
WO2004005489A2 (en) Nucleic acids encoding sarcocystic neurona antigen and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120403

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121228

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130128